Respiratory syncytial virus vaccine development.

Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. OMICS (2011) 1.21

Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats. PLoS One (2012) 1.21

The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathways. Mol Cell Proteomics (2012) 1.08

An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children. BMC Public Health (2011) 1.03

A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol J (2010) 1.02

A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J (2011) 1.01

An adjuvanted respiratory syncytial virus fusion protein induces protection in aged BALB/c mice. Immun Ageing (2012) 0.92

Replacement of previously circulating respiratory syncytial virus subtype B strains with the BA genotype in South Africa. J Virol (2011) 0.91

Respiratory syncytial virus infections in infants affected by primary immunodeficiency. J Immunol Res (2014) 0.83

Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice. PLoS One (2012) 0.80

Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity. Paediatr Respir Rev (2015) 0.78

Immunological, Viral, Environmental, and Individual Factors Modulating Lung Immune Response to Respiratory Syncytial Virus. Biomed Res Int (2015) 0.76

Respiratory syncytial virus prevention in children with congenital heart disease: who and how? Korean J Pediatr (2011) 0.75

Human CD8(+) T Cells Target Multiple Epitopes in Respiratory Syncytial Virus Polymerase. Viral Immunol (2016) 0.75

Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics (1998) 49.00

Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA (2003) 31.71

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol (1969) 10.85

Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med (2005) 9.47

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol (1969) 6.85

Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol (1969) 4.97

Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol (1969) 4.93

Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine (1990) 4.37

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79

Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol (2002) 3.74

Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest (1991) 3.71

Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol (1986) 3.64

Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis (1991) 3.27

Viral and host factors in human respiratory syncytial virus pathogenesis. J Virol (2007) 3.19

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med (2008) 3.17

Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90

Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun (1984) 2.86

Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol (1992) 2.25

Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis (1982) 2.17

Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol (1991) 2.05

Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol (2000) 1.97

Immune responses and disease enhancement during respiratory syncytial virus infection. Clin Microbiol Rev (2005) 1.94

The coming of age of virus-like particle vaccines. Biol Chem (2008) 1.85

Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector. J Virol (2006) 1.73

Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol (1998) 1.66

Low-temperature-grown RS virus in adult volunteers. JAMA (1968) 1.63

Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol (1988) 1.60

New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc (2005) 1.58

CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells. Clin Exp Immunol (1992) 1.57

Immunization with glycoprotein subunits of respiratory syncytial virus to protect cotton rats against viral infection. J Infect Dis (1987) 1.51

Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine (2003) 1.48

A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology (1998) 1.47

Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc (2005) 1.42

Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease. Vaccine (1989) 1.35

Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. J Virol (2002) 1.34

A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV. Vaccine (1993) 1.33

Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol (1999) 1.30

The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis (2006) 1.30

Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs (2006) 1.27

Effects of human metapneumovirus and respiratory syncytial virus antigen insertion in two 3' proximal genome positions of bovine/human parainfluenza virus type 3 on virus replication and immunogenicity. J Virol (2003) 1.26

Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol (2007) 1.24

Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3. J Virol (2001) 1.24

Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein. Virology (1991) 1.19

Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys. J Virol (2004) 1.18

Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology (1997) 1.14

Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA. Vaccine (1999) 1.14

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine (1996) 1.12

Analysis of the respiratory syncytial virus fusion protein using monoclonal and polyclonal antibodies. J Gen Virol (1986) 1.12

Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis (2008) 1.11

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine (1997) 1.09

The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine (1999) 1.09

Respiratory syncytial virus (RSV)-induced airway hyperresponsiveness in allergically sensitized mice is inhibited by live RSV and exacerbated by formalin-inactivated RSV. J Infect Dis (2000) 1.06

Monophosphoryl lipid A adjuvant reverses a principal histologic parameter of formalin-inactivated respiratory syncytial virus vaccine-induced disease. Vaccine (2001) 1.05

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis (1998) 1.04

Intranasal gene transfer by chitosan-DNA nanospheres protects BALB/c mice against acute respiratory syncytial virus infection. Hum Gene Ther (2002) 1.04

Recombinant Sendai virus as a novel vaccine candidate for respiratory syncytial virus. Viral Immunol (2005) 1.02

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J (1996) 1.02

Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med (1998) 1.01

Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine (2003) 0.99

Evaluation in chimpanzees of vaccinia virus recombinants that express the surface glycoproteins of human respiratory syncytial virus. Vaccine (1990) 0.98

T cell source of type 1 cytokines determines illness patterns in respiratory syncytial virus-infected mice. J Clin Invest (1997) 0.98

Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis (1993) 0.97

Respiratory syncytial virus and T cells: interplay between the virus and the host adaptive immune system. Proc Am Thorac Soc (2005) 0.93

Evaluation of BBG2Na in infant macaques: specific immune responses after vaccination and RSV challenge. Vaccine (2004) 0.92

Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model. Vaccine (2007) 0.92

Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J (1994) 0.91

Vaccination of cotton rats with a chimeric FG glycoprotein of human respiratory syncytial virus induces minimal pulmonary pathology on challenge. J Infect Dis (1991) 0.89

Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes. J Virol (2006) 0.89

Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate. Virology (2000) 0.89

Monoclonal antibodies protect against respiratory syncytial virus. Lancet (1983) 0.88

Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis (1993) 0.88

Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers. Vaccine (1993) 0.87

Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine (2007) 0.85

Adjuvants recognized by toll-like receptors inhibit the induction of polarized type 2 T cell responses by natural attachment (G) protein of respiratory syncytial virus. Vaccine (2003) 0.85

Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection. Arch Virol (1991) 0.84

Sub-nucleocapsid nanoparticles: a nasal vaccine against respiratory syncytial virus. PLoS One (2008) 0.84

Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic. Virology (2001) 0.83

Respiratory syncytial virus infection of gene gun vaccinated mice induces Th2-driven pulmonary eosinophilia even in the absence of sensitisation to the fusion (F) or attachment (G) protein. Vaccine (2000) 0.83

Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides. Vaccine (2000) 0.83

Complete protection of mice from respiratory syncytial virus infection following mucosal delivery of synthetic peptide vaccines. Vaccine (1999) 0.80

Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine (2004) 0.80

Respiratory syncytial virus recombinant F protein (residues 255-278) induces a helper T cell type 1 immune response in mice. Viral Immunol (2007) 0.79

Current research on respiratory viral infections: Fourth International Symposium. Antiviral Res (2002) 0.79

Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice. Vaccine (2012) 0.81